On Friday, Johnson & Johnson announced that its single-dose vaccine was 72 per cent effective in preventing COVID-19, but only 66 per cent was observed globally in a large trial.
The trial had 44,000 volunteers, in which the level of protection against both moderate and severe COVID-19 was 66 per cent in Latin America and 57 per cent in South Africa, where the COVID-19 variant is circulating.
Read more from the News Source HERE